These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 9717679

  • 1. Comparative study of reactogenicity and immunogenicity of new and established measles, mumps and rubella vaccines in healthy children.
    Usonis V, Bakasenas V, Chitour K, Clemens R.
    Infection; 1998; 26(4):222-6. PubMed ID: 9717679
    [Abstract] [Full Text] [Related]

  • 2. Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children.
    Usonis V, Bakasenas V, Kaufhold A, Chitour K, Clemens R.
    Pediatr Infect Dis J; 1999 Jan; 18(1):42-8. PubMed ID: 9951979
    [Abstract] [Full Text] [Related]

  • 3. Reactogenicity and immunogenicity of a new combined measles-mumps-rubella vaccine: results of a multicentre trial. The Cooperative Group for the Study of MMR vaccines.
    Crovari P, Gabutti G, Giammanco G, Dentico P, Moiraghi AR, Ponzio F, Soncini R.
    Vaccine; 2000 Jun 15; 18(25):2796-803. PubMed ID: 10812221
    [Abstract] [Full Text] [Related]

  • 4. A new measles mumps rubella (MMR) vaccine: a randomized comparative trial for assessing the reactogenicity and immunogenicity of three consecutive production lots and comparison with a widely used MMR vaccine in measles primed children.
    Lee CY, Tang RB, Huang FY, Tang H, Huang LM, Bock HL.
    Int J Infect Dis; 2002 Sep 15; 6(3):202-9. PubMed ID: 12718836
    [Abstract] [Full Text] [Related]

  • 5. A randomized comparative trial in order to assess the reactogenicity and immunogenicity of a new measles mumps rubella (MMR) vaccine when given as a first dose at 12-24 months of age.
    Gatchalian S, Cordero-Yap L, Lu-Fong M, Soriano R, Ludan A, Chitour K, Bock HL.
    Southeast Asian J Trop Med Public Health; 1999 Sep 15; 30(3):511-7. PubMed ID: 10774661
    [Abstract] [Full Text] [Related]

  • 6. [Drug clinics. Drug of the month. A new measles-rubella-mumps vaccine (Priorix)].
    Senterre J.
    Rev Med Liege; 1999 Feb 15; 54(2):122-4. PubMed ID: 10221066
    [Abstract] [Full Text] [Related]

  • 7. Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: A phase III, randomized study.
    Abu-Elyazeed R, Jennings W, Severance R, Noss M, Caplanusi A, Povey M, Henry O.
    Hum Vaccin Immunother; 2018 Feb 15; 14(11):2624-2631. PubMed ID: 29902133
    [Abstract] [Full Text] [Related]

  • 8. Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella.
    Wellington K, Goa KL.
    Drugs; 2003 Feb 15; 63(19):2107-26. PubMed ID: 12962524
    [Abstract] [Full Text] [Related]

  • 9. Antibodies to measles, mumps and rubella in UK children 4 years after vaccination with different MMR vaccines.
    Miller E, Hill A, Morgan-Capner P, Forsey T, Rush M.
    Vaccine; 1995 Jun 15; 13(9):799-802. PubMed ID: 7483800
    [Abstract] [Full Text] [Related]

  • 10. Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study.
    Klein NP, Abu-Elyazeed R, Povey M, Macias Parra M, Diez-Domingo J, Ahonen A, Korhonen T, Tinoco JC, Weiner L, Marshall GS, Silas PE, Sarpong KO, Ramsey KP, Fling JA, Speicher D, Campos M, Munjal I, Peltier C, Vesikari T, Baccarini C, Caplanusi A, Gillard P, Carryn S, Henry O.
    J Pediatric Infect Dis Soc; 2020 Apr 30; 9(2):194-201. PubMed ID: 30849175
    [Abstract] [Full Text] [Related]

  • 11. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella.
    Tischer A, Gerike E.
    Vaccine; 2000 Jan 31; 18(14):1382-92. PubMed ID: 10618536
    [Abstract] [Full Text] [Related]

  • 12. Comparison of immunogenicity and reactogenicity of a measles, mumps and rubella (MMR) vaccine in German children vaccinated at 9-11, 12-14 or 15-17 months of age.
    Klinge J, Lugauer S, Korn K, Heininger U, Stehr K.
    Vaccine; 2000 Jul 15; 18(27):3134-40. PubMed ID: 10856793
    [Abstract] [Full Text] [Related]

  • 13. A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration.
    MMR-158 Study Groupa See Contributors section..
    Hum Vaccin Immunother; 2019 Jul 15; 15(4):786-799. PubMed ID: 30785357
    [Abstract] [Full Text] [Related]

  • 14. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine.
    Nolan T, McIntyre P, Roberton D, Descamps D.
    Vaccine; 2002 Dec 13; 21(3-4):281-9. PubMed ID: 12450703
    [Abstract] [Full Text] [Related]

  • 15. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
    Zäch K, Nicoara C, Germann D, Matter L.
    Schweiz Med Wochenschr; 1998 Apr 25; 128(17):649-57. PubMed ID: 9622837
    [Abstract] [Full Text] [Related]

  • 16. Serologic responses to measles, mumps, and rubella (MMR) vaccine in healthy infants: failure to respond to measles and mumps components may influence decisions on timing of the second dose of MMR.
    Mitchell LA, Tingle AJ, Décarie D, Lajeunesse C.
    Can J Public Health; 1998 Apr 25; 89(5):325-8. PubMed ID: 9813922
    [Abstract] [Full Text] [Related]

  • 17. Safety and Immunogenicity of Human Serum Albumin-Free MMR Vaccine in US Children Aged 12-15 Months.
    Mufson MA, Diaz C, Leonardi M, Harrison CJ, Grogg S, Carbayo A, Carlo-Torres S, JeanFreau R, Quintero-Del-Rio A, Bautista G, Povey M, Da Costa C, Nicholson O, Innis BL.
    J Pediatric Infect Dis Soc; 2015 Dec 25; 4(4):339-48. PubMed ID: 26582873
    [Abstract] [Full Text] [Related]

  • 18. Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15 months: A phase III, randomized, non-inferiority trial.
    MMR-161 Study Group.
    Vaccine; 2018 Sep 11; 36(38):5781-5788. PubMed ID: 30104117
    [Abstract] [Full Text] [Related]

  • 19. Safety, reactogenicity and immunogenicity of the live attenuated combined measles, mumps and rubella vaccine containing the RIT 4385 mumps strain in healthy Singaporean children.
    Lim FS, Han HH, Bock HL.
    Ann Acad Med Singap; 2007 Dec 11; 36(12):969-73. PubMed ID: 18185875
    [Abstract] [Full Text] [Related]

  • 20. Safety and immunogenicity of concurrent administration of measles-mumps-rubella-varicella vaccine and PedvaxHIB vaccines in healthy children twelve to eighteen months old. The MMRV Study Group.
    Reuman PD, Sawyer MH, Kuter BJ, Matthews H.
    Pediatr Infect Dis J; 1997 Jul 11; 16(7):662-7. PubMed ID: 9239770
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.